The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Screening for EGFR, KRAS, and PIK3CA mutations in well-characterized, immunohistochemically confirmed squamous cell carcinoma of lung.
N. Rekhtman
No relevant relationships to disclose
P. K. Paik
No relevant relationships to disclose
M. E. Arcila
No relevant relationships to disclose
L. J. Tafe
No relevant relationships to disclose
M. F. Zakowski
No relevant relationships to disclose
G. J. Riely
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim
V. A. Miller
Consultant or Advisory Role - ArQule; Boehringer Ingelheim; Genentech; OSI Pharmaceuticals; Pfizer; Roche
M. G. Kris
Consultant or Advisory Role - Boehringer Ingelheim; Pfizer
M. Ladanyi
No relevant relationships to disclose